TY - JOUR
T1 - Outcomes of inferonasal Baerveldt glaucoma drainage implant surgery
AU - Harbick, Kara Hoffman
AU - Sidoti, Paul A.
AU - Budenz, Donald L.
AU - Venkatraman, Anna
AU - Bruther, Megan
AU - Grayson, Douglas K.
AU - Ko, Anne
AU - Yi, Glara N.
PY - 2006/2
Y1 - 2006/2
N2 - Purpose: To determine the outcomes of inferonasal Baerveldt glaucoma implant (BGI) surgery. Patients and Methods: A retrospective, non-comparative case series of 182 eyes of 182 patients who underwent inferonasal placement of a Baerveldt glaucoma implant. The main outcome measures included intraocular pressure, number of glaucoma medications, best corrected visual acuity, and complications. Results: Patients were followed for an average (± SD) of 19 ± 15 months. Median Snellen visual acuity was unchanged at last follow-up. Intraocular pressure was reduced from a mean (± SD) of 28.6 ± 11.5 mm Hg preoperatively to 13.4 ± 5.7 mm Hg at most recent follow-up (P < 0.001). The number of antiglaucoma medications was reduced from a mean (± SD) of 2.7 ± 1.3 preoperatively to 1.1 ± 1.1 at most recent follow-up. Nineteen eyes met our criteria for failure, yielding a cumulative percent survival of 92% at 12 months, 88% at 24 months, and 77% at 44 months. The most common complications were hyphema (14 eyes, 8%), choroidal effusion (12 eyes, 7%), and corneal decompensation (19 eyes, 10%). Endophthalmitis and diplopia occurred rarely (1 eye, <1%; 3 eyes, 2%, respectively). Conclusions: Inferonasal Baerveldt glaucoma implant placement appears to be a safe and effective surgical option that may be helpful in certain clinical situations.
AB - Purpose: To determine the outcomes of inferonasal Baerveldt glaucoma implant (BGI) surgery. Patients and Methods: A retrospective, non-comparative case series of 182 eyes of 182 patients who underwent inferonasal placement of a Baerveldt glaucoma implant. The main outcome measures included intraocular pressure, number of glaucoma medications, best corrected visual acuity, and complications. Results: Patients were followed for an average (± SD) of 19 ± 15 months. Median Snellen visual acuity was unchanged at last follow-up. Intraocular pressure was reduced from a mean (± SD) of 28.6 ± 11.5 mm Hg preoperatively to 13.4 ± 5.7 mm Hg at most recent follow-up (P < 0.001). The number of antiglaucoma medications was reduced from a mean (± SD) of 2.7 ± 1.3 preoperatively to 1.1 ± 1.1 at most recent follow-up. Nineteen eyes met our criteria for failure, yielding a cumulative percent survival of 92% at 12 months, 88% at 24 months, and 77% at 44 months. The most common complications were hyphema (14 eyes, 8%), choroidal effusion (12 eyes, 7%), and corneal decompensation (19 eyes, 10%). Endophthalmitis and diplopia occurred rarely (1 eye, <1%; 3 eyes, 2%, respectively). Conclusions: Inferonasal Baerveldt glaucoma implant placement appears to be a safe and effective surgical option that may be helpful in certain clinical situations.
KW - Baerveldt
KW - Glaucoma drainage implant
KW - Inferonasal
UR - http://www.scopus.com/inward/record.url?scp=30344479728&partnerID=8YFLogxK
U2 - 10.1097/01.ijg.0000195597.30600.27
DO - 10.1097/01.ijg.0000195597.30600.27
M3 - Article
C2 - 16378010
AN - SCOPUS:30344479728
SN - 1057-0829
VL - 15
SP - 7
EP - 12
JO - Journal of Glaucoma
JF - Journal of Glaucoma
IS - 1
ER -